We expected to detect frequent mutations of KRAS, which frequently (50–60%) occur in gallbladder and biliary tract cancers of patients with pancreaticobiliary maljunction because of regurgitation of bile and pancreatic fluid30. Here, KRAS is linked to biliary tract neoplasm.